Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec. The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...
The China patent office’s re-examination board has upheld June 2015 rejection of a critical sofosbuvir patent, denying Gilead’s appeal on I-MAK’s winning case. The patent office ruled that the sofosbuvir prodrug did not deserve a patent under the law. This comes as I-MAK just filed a new legal challenge against the sofosbuvir base compound in China on April 19th, 2017. Freeing sofosbuvir of its unmerited patents in the country would open the door to affo
Chinese biotech Ascletis has raised $100 million in a second-round financing as it prepares for the launch of its first commercial product – a danoprevir/ravidasvir combination. Hangzhou-based Ascletis is vying to become the first to claim approval for an interferon-free hepatitis C virus combination therapy in China, and says the cash injection will be used to expand its product portfolio into other areas such as hepatitis B virus, as well as build its s
Hepatitis C patients in China will soon be able to access direct-acting antiviral treatments, which can thoroughly cure the liver infection, a senior liver disease specialist said. "Several DAA medicines are expected to get approval from the top drug authority and enter the Chinese market early next year, which will bring China's hepatitis C treatment in line with international mainstream practices," said Wei Lai, president of the Chinese Society of Liver
Chinese people in the past have gone to the U.S. to for cancer treatment and have snatched up cold medicine and painkillers on trips to Japan. Chinese now go overseas for another medical purpose: curing their liver diseases.Although treatment of the virus has gone through revolutionary development in the last few years, none of the direct-acting antiviral agents which have shown to cure more than 90% of patients within a few months, have yet been approved
TWO heads of a hospital in northwest China's Shaanxi Province were sacked after 26 patients contracted hepatitis C during dialysis treatment, local authorities said Friday.The president and a deputy president of Zhen'an County Hospital in Shangluo City were removed from their posts, and 13 other employees received administrative penalties, including admonitions and demerits on their records, a source with the county's health and family planning bureau said
Physician, patient, and health justice groups including the Initiative for Medicines, Access and Knowledge (I-MAK) are mounting legal challenges to Gilead Sciences' patent to sofosbuvir in several middle-income countries including Argentina, Brazil, China, Russia and Ukraine. Read more...http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html...